Dosing in obesity: A simple solution to a big problem

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 5, 2007, Pages 505-508

  Han, P Y ^a   Duffull, S B ^a,b   Kirkpatrick, C M J ^a   Green, B ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN;

BODY COMPOSITION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXPOSURE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOTHESIS; MEDICAL RESEARCH; OBESITY; PRIORITY JOURNAL; REVIEW;

BODY COMPOSITION; BODY WEIGHT; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; OBESITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SEX FACTORS;

EID: 35448941550     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100381     Document Type: Review

References (14)

1. World Health Organization. Global database on body mass index (BMI) [online database] 〈http://www.who.int/bmi〉 (2006).
2. Green, B. & Duffull, S.B. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br. J. Clin. Pharmacol. 58, 119-133 (2004).
3. U.S. Food and Drug Administration. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products 〈http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html〉 (2004).
4. Roubenoff, R. & Kehayias, J.J. The meaning and measurement of lean body mass. Nutr. Rev. 49, 163-175 (1991).
5. Forbes, G.B. & Welle, S.L. Lean body mass in obesity. Int J. Obes. 7, 99-107 (1983).
6. James, W. Research on Obesity (Her Majesty's Stationery Office, London, 1976).
7. Emery, M.G. et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 38, 428-435 (2003).
8. Green, B. & Duffull, S.B. Caution when lean body weight is used as a size descriptor for obese subjects. Clin. Pharmacol. Ther. 72, 743-744 (2002).
9. Janmahasatian, S., Duffull, S.B., Ash, S., Ward, L.C., Byrne, N.M. & Green, B. Quantification of lean bodyweight. Clin. Pharmacokinet. 44, 1051-1065 (2005).
10. Devine, D. Case study number 25 gentamicin therapy. Drug Intell. Clin. Pharm. 8, 650-655 (1974).
11. Green, B. Dosing of Enoxaparin in Obese Patients (University of Queensland, Brisbane, 2002).
12. Peck, C.C. & Cross, J.T. "Getting the dose right": Facts, a blueprint, and encouragements. Clin. Pharmacol. Ther. 82, 12-14 (2007).
13. Shibutani, K., Inchiosa, M.A. Jr, Sawada, K. & Bairamian, M. Accuracy of pharmacokinetic models for predicting plasma fentanyl concentrations in lean and obese surgical patients. Anesthesiology 101, 603-613 (2004).
14. Sheiner, L.B. Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61, 275-291 (1997).